Company page

Transgene Sa

Transgene Sa, traded under the ticker TNG, is a public company based in France with a market capitalization of approximately €269.4 million. The company focuses on developing innovative immunotherapy treatments for cancer and infectious diseases. Transgene is committed to advancing its proprietary technologies and expanding its pipeline to address unmet medical needs.